Abbott Laboratories : 4Q 2021 Earnings Infographic

FOURTH-QUARTER

AND FULL-YEAR

2021 RESULTS

TOTAL COMPANY

BUSINESS HIGHLIGHTS

	WORLDWIDE SALES		GROWTH ON AN
					ORGANIC BASIS*
	Q4	$11.5B	Q4	+7.7%1
	FULL	$43.1B	FULL	+22.9%
				2
	YEAR				YEAR
	YEAR	$5.21		REFLECTS NEARLY
		43%
	FULL			3			4
		ADJUSTED		GROWTH VERSUS
		DILUTED EPS	PRIOR YEAR

LEADING IN HEALTH TECH

$1.0B Q4 FREESTYLE LIBRE®† SALES

Now approaching 4 million users globally

15.8%8 GROWTH IN MEDICAL DEVICES

on an organic basis* compared to pre-pandemic sales in 2019

FULL-YEAR 2021: KEY BUSINESS UNITS5	ADVANCING OUR
GROWTH ON AN ORGANIC BASIS*									VIRTUAL CLINIC
										R&D PIPELINE
											NEUROSPHERE™
+19.4%						+42.7%		New product introductions and
					approvals across our portfolio, including
	MEDICAL DEVICES							DIAGNOSTICS	several in large, fast-growing markets
										Highlights include expanded
+7.7%	+10.4%		reimbursement coverage for
	MitraClip® and launch of NeuroSphere™
	Virtual Clinic for remote treatment
	NUTRITION							ESTABLISHED	chronic pain or movement disorders
								PHARMACEUTICALS

ISSUED FULL-YEAR 2022 EPS GUIDANCE	STEPPING U P
AT LEAST		REFLECTS	ON TESTING
	the start of the pandemic
$4.70		45%
6		7	More than 1.4 billion COVID
			tests distributed globally since
IN ADJUSTED		GROWTH	Excluding COVID-19testing-related
DILUTEDEPS		COMPARED
		TO 2019	sales, fourth-quarterDiagnostics sales
			increased8.7%9 on an organic basis*

*Organic sales growth excludes impactof foreign exchange. For full financialdata and reconciliation of non-GAAP measures, please see our press release datedJan. 26, 2022, available at www.abbottinvestor.com. 1. On a GAAP basis, fourth-quarterAbbott sales increased 7.2%.

2. On a GAAP basis, full-year 2021 Abbott sales increased 24.5%. 3. Full-year2021 GAAP diluted EPS from continuing operations was $3.94. 4. Full-year 2021 diluted EPS from continuing operations on a GAAP basis reflects 58% growth. 5. On a GAAP basis, full-year 2021

Medical Devices salesincreased 21.9%; Diagnostics sales increased 44.8%; Nutrition sales increased 8.5%; Established Pharmaceuticals sales increased9.6%. 6. Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43.

Abbott forecastsspecified items for the full-year 2022 of $1.27 per share primarily related to intangible amortization, restructuringand cost reductioninitiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted

earnings pershare from continuing operations would be at least $4.70 for the full-year2022. 7. Ona GAAP basis, full-year2022 projectedadjusted diluted EPS from continuing operations reflects 67% growth compared to 2019. Full-year 2019 diluted EPS from continuing

operationswas $2.06 on a GAAP basis and $3.24 on an adjusted basis.8. Ona GAAP basis, Medical Devices full-year2021sales increased17.0% compared to sales in 2019. 9. On a GAAP basis excluding COVID-19testing-related sales, fourth-quarter Diagnostics sales

increased8.2%. †Find important safety information about the FreeStyle® Libre portfolio: www.freestylelibre.us/safety-information.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private SecuritiesLitigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technologicaland other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publiclyany revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.